Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Aquaporin 4 (AQP4) is a protein involved in the permeability of water. The AQP4 gene is located at the junction of human chromosome 18q11.2 and q12.1 and contains four exons. AQP4 is mainly distributed in supporting cells such as astrocytes, choroid plexus epithelial cells and ependymal epithelial cells in the central nervous system. AQP4 is abundantly expressed in astrocyte foot processes, glial conjunctiva, pia mater and chamber. The membrane is in the interstitial space of its underlying astrocytes. It has not been found to be expressed in excitatory cells. Gundersen et al. found that AQP4 is polarly distributed on astrocyte foot processes, and anchoring proteins and cell surrounding environment play a role in this distribution. Therefore, it can be inferred that it is related to the water balance of the central system by the distribution and expression characteristics of AQP4. A large number of studies have shown that AQP4 is not only closely related to the occurrence and development of cerebral edema but also participates in the pathological process of various neurological diseases, which is of great significance for the diagnosis and treatment of clinical nervous system diseases.
Inwardly rectifying K+ channel (Kir4.1) is a membrane of the central nervous system. Studies have shown that AQP4 and Kir4.1 have a co-coupled relationship in structure and function. The C-terminus of both is anchored to the cell membrane of glial cells by the PDZ domain of α-syntrophin. Changes in AQP4 expression can affect the movement of water molecules inside and outside the cell, which in turn leads to changes in potassium ion permeability in Kir4.1, and corresponding potential changes occur. Under pathological conditions, the expression of AQP4 was significantly increased in the hippocampus of patients with temporal lobe epilepsy, while that of Kir4.1 was down-regulated. Potassium ion balance is disrupted, and the anchoring protein complex of AQP4 and Kir4.1 is impaired. This suggests that both may participate in the pathological process of epilepsy through the functional coupling.
AQP4 and Brain Edema
A large number of studies have shown that elevated AQP4 expression is the main cause of brain edema caused by traumatic brain injury. Pizzo et al. found that AQP4 can effectively assess the severity of cerebral edema by detecting the level of AQP4 in cerebrospinal fluid after traumatic brain injury. The degree of edema around the hematoma after cerebral hemorrhage is independently related to the variation of the AQP4 gene. It has been studied to produce a rat water poisoning model by knocking out the AQP4 gene, and the brain tissue water content is lower than that of the water poisoning model produced by ordinary rats. And its degree of swelling around the perivascular astrocyte foot processes is also lower. It is speculated that AQP4 plays a promoting role in the occurrence and development of brain edema.
Many studies have shown that the expression of AQP4 plays a positive role in cytotoxic cerebral edema and reverses in vasogenic cerebral edema. In cytotoxic cerebral edema, the blood-brain barrier is not destroyed, and water molecules enter the brain tissue through AQP4. Therefore, when the expression of AQP4 is elevated, the more water that enters the brain tissue, the more severe the cerebral edema. In vasogenic cerebral edema, upregulation of AQP4 reduces the extent of cerebral edema. This may be because the blood-brain barrier is destroyed, and serum proteins and isotonic fluids penetrate into the intercellular space in order to adapt to changes in hydrostatic pressure, causing swelling of the intercellular space. Therefore, the formation of vasogenic cerebral edema is not involved in AQP4, but the release of water molecules during its development requires AQP4 as a mediator. Therefore, AQP4 inhibits cerebral edema in this process.
Karmacharya et al. found that the application of low-intensity ultrasound stimulation in a rat brain edema model can reduce local aggregation of AQP4. Compared with the control group, the water content of brain tissue and the expression of AQP4 were significantly reduced. Other aspects such as hypothermia treatment, decompressive craniectomy, dexamethasone and other treatments can alleviate brain edema by inhibiting the expression of AQP4, improve prognosis and improve survival rate. It is speculated that it is feasible to use AQP4 as a therapeutic target to alleviate brain edema caused by various causes.
AQP4 and Brain Tumor
glioma is the primary brain tumor with the highest incidence of the nervous system in the clinic, and it is mostly malignant invasive growth. The total surgical resection rate is low and the recurrence rate is high. It is necessary to cooperate with radiotherapy and chemotherapy and other comprehensive treatment. It is still very difficult to treat. The study found that in brain astrocytoma, high expression of AQP4 is closely related to the occurrence of peritumoral edema and the degree of malignancy of glioma. Ding et al. have shown that AQP4 is significantly increased in brain tumor cells, and glioma is more prominent. AQP4 is very likely to have a positive effect on tumor growth and promote the deterioration of the disease. AQP4 has anti-apoptotic effects in glioma cells. In addition, AQP4 can promote the migration of glioma cells, which will undoubtedly promote tumor growth and increase its invasiveness. It is speculated that artificially promoting the down-regulation of AQP4 may have an inhibitory effect on the development of glioma.
Figure 1: The new potential roles of AQP4 in glioma. (Lan, et al. 2017).
Meningioma is the intracranial tumor with a second highest incidence of glioma. Studies have shown that AQP4 is mainly expressed on the tumor cell membrane of meningioma, and its expression level is positively correlated with the severity of peritumoral edema. Therefore, it is speculated that if the AQP4 expression of tumor cells can be inhibited, peritumoral edema can be controlled. It can alleviate the symptoms of increased intracranial pressure during the operation period, reduce the risk of brain swelling during surgery and it is easier to separate tumors during surgery and reduce damage to brain tissue.
Multiple intracranial metastases are caused by tumor metastasis to the brain in other parts of the body. Men are more likely to metastasize with lung cancer, while women are more likely to metastasize to breast cancer and can be transferred to any part of the brain. Zhao et al. found that there is a large amount of AQP4 expression in the peritumoral brain tissue of multiple intracranial metastases, but there is a little AQP4 expression in tumor tissue. AQP4 was slightly stained in the brain tissue farther away from the tumor, and as the tumor approached, the AQP4 staining in the surrounding brain tissue continued to deepen. It is speculated that the expression of AQP4 is closely related to the edema of the brain tissue surrounding the multiple metastases and is a positive relation.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.